Walvax Biotechnology (SHE:300142) amended its exclusive sub-license with US-based Notitia Biotechnologies, according to a Thursday filing with the Shenzhen bourse.
The addition includes non-patient applications of core microbiome analysis, microbiota-targeted transplantation and nutritional formulation technologies in China, Hong Kong and Macau.
Walvax Biotechnology will pay $1.5 million in upfront fees and 6.5% royalties as well as milestone payments related to approvals and sales targets.
Shares of the pharmaceutical company were down 2% Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments